OBJECTIVE- To evaluate whether hyperfibrinogenemia represents a compon
ent of the metabolic syndrome. RESEARCH DESIGN AND METHODS- A cross-se
ctional study was conducted on the relation between fibrinogen and the
metabolic syndrome in a working population of 1,252 nondiabetic men,
aged 35-64 years, randomly selected among all men participating in a h
ealth screening. We measured anthropometric characteristics, blood pre
ssure, fasting plasma fibrinogen, cholesterol (total, LDL, and HDL), t
riglycerides, glucose, and insulin. Individuals with two or more metab
olic abnormalities (defined as being in the highest quartile of the di
stribution of diastolic blood pressure, plasma glucose, or triglycerid
es or being in the lowest quartile of HDL cholesterol) were considered
to have the metabolic syndrome. RESULTS- Age-adjusted fibrinogen leve
ls correlated significantly with BMI, waist-to-hip ratio, systolic and
diastolic blood pressure, plasma total cholesterol, LDL cholesterol,
triglycerides, insulin, and HDL cholesterol (inversely). Subjects with
the metabolic syndrome had significantly higher plasma fibrinogen lev
els than those without (285.1 +/- 1.9 vs. 300.2 +/- 3.0 mg/dl, mean +/
- SE, P = 0.0001). Plasma fibrinogen concentrations and the prevalence
of hyperfibrinogenemia (defined as greater than or equal to 350 mg/dl
) increased progressively from 279 to 307 mg/dl ( = 0.0001) and from 9
to 22% (P = 0.0024), respectively, across categories with an increasi
ng number of metabolic disorders characterizing the syndrome (only one
, any two, three or more). In multivariate analyses, both plasma insul
in and the metabolic syndrome were significantly and independently ass
ociated with plasma fibrinogen. CONCLUSIONS- The finding suggests that
hyperfibrinogenemia may be considered a component of the metabolic sy
ndrome. This may also explain the increased cardiovascular risk associ
ated with hyperinsulinemia/insulin resistance.